Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)
ID: 353519Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353519

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-203.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for research focused on the neuropathological interactions between COVID-19 and Alzheimer’s disease-related dementias (ADRD). This initiative invites proposals for studies utilizing animal, cell culture, and human tissue models to investigate how COVID-19 affects cognitive decline in individuals with existing ADRD, accelerates ADRD pathology, and exacerbates neurological outcomes in those at risk. The funding opportunity aims to enhance understanding of the long-term neurological implications of COVID-19, with a total funding amount of up to $3.75 million available for up to five awards, each capped at $500,000 per year for a maximum of five years. Applications will be accepted starting September 4, 2024, with a final submission deadline of October 5, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-203-Full-Announcement.html
    PAR-24-203.html
    The National Institutes of Health (NIH) has issued a Notice of Funding Opportunity (NOFO) for research investigating the neuropathological interactions between COVID-19 and Alzheimer’s disease-related dementias (ADRD). This initiative invites applicants to propose studies utilizing animal, cell culture, and human tissue models to explore mechanisms by which COVID-19 affects ADRD. Key objectives include examining how COVID-19 impacts cognitive decline in those already affected by ADRD, accelerates ADRD pathology, and exacerbates neurological outcomes in individuals with pre-existing ADRD. The funding opportunity is set to provide up to $3.75 million, supporting up to five awards, with budgets capped at $500,000 in direct costs per year for a maximum of five years. The application submission window opens on September 4, 2024, with a final deadline of October 5, 2024. Various organizations—including higher education institutions, nonprofits, and foreign entities—are eligible to apply, but clinical trials are not permitted under this initiative. The overarching aim is to advance understanding of the long-term neurological implications of COVID-19, contributing to public health knowledge and informing future interventions for ADRD.
    Similar Opportunities
    Mechanisms Underlying Olfactory Dysfunction in Aging and Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) aimed at investigating the mechanisms underlying olfactory dysfunction in aging, Alzheimer’s disease (AD), and Alzheimer’s disease-related dementias (ADRD). This initiative seeks to explore the relationship between olfactory decline and various health outcomes in older adults, potentially identifying novel therapeutic targets for disease modification. The research may involve studies on older adults and animal models, utilizing diverse methodologies such as cellular, molecular, and imaging techniques. While applications are not currently being solicited, interested researchers are encouraged to prepare collaborative projects in anticipation of the funding opportunity, which is expected to utilize the R01 activity code. For further inquiries, contact Coryse St. Hillaire-Clarke, Ph.D., at 301-496-9350 or via email at sthillaireclacn@mail.nih.gov. The estimated synopsis post date is August 6, 2026, with a closing date for applications anticipated on October 6, 2026, and awards expected to be made by July 6, 2027.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" aimed at advancing exploratory research in Alzheimer's disease (AD) and related dementias (ADRD). This initiative invites applications for innovative methodologies, animal models, and techniques that require preliminary data, with a focus on addressing health disparities among under-resourced populations. The program emphasizes the importance of interdisciplinary research to combat the public health crisis posed by AD and ADRD, with a maximum funding amount of $275,000 available over two years. Interested applicants must submit their proposals by November 16, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting early- and late-stage clinical trials focused on Alzheimer's Disease (AD), Alzheimer's Disease-Related Dementias (ADRD), and age-related cognitive decline. This initiative seeks applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive, behavioral, and neuropsychiatric changes associated with these conditions, as well as studies to enhance trial design and methodologies. The funding opportunity, categorized under health-related discretionary grants, is intended for small businesses with expertise in aging research, with an estimated synopsis posting date of August 1, 2025, and a closing date for applications expected by October 5, 2025. For further inquiries, interested applicants can contact Laurie Ryan, Ph.D., at 301-496-9350 or via email at ryanl@mail.nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD) through the R01 Clinical Trial Optional grant program. This initiative aims to support innovative research that addresses significant biomedical, social, and behavioral aspects of aging, with a focus on inclusivity and diversity in participant recruitment. Given the projected rise in expenditures for AD-related care, which could exceed $1 trillion by 2050, this funding is critical for advancing understanding and treatment of dementia-related challenges. Interested applicants can find more information and submission guidelines at the NIH grants website, with applications due by November 5, 2027, and no specific budget limits outlined.
    Notice of Intent to Publish a Notice of Funding Opportunity for Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for early- and late-stage clinical trials focused on Alzheimer's Disease, Alzheimer's Disease-Related Dementias, and age-related cognitive decline. This initiative aims to invite applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive and behavioral changes associated with these conditions, as well as to enhance trial design and methodologies. The NOFO is expected to be published in December 2024, with application due dates in March, June, and October of 2025, and an estimated award date set for December 1, 2025. Interested applicants are encouraged to prepare collaborative projects in advance, as there are no cost-sharing requirements associated with this grant opportunity.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 exploratory research grant focused on understanding neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity aims to enhance knowledge of the neurobiological and behavioral mechanisms underlying symptoms such as aggression, anxiety, and agitation, which significantly impact patient care and outcomes. The initiative is part of a broader national effort to address the complexities of Alzheimer's care, with funding capped at $275,000 over two years, and applications opening on January 16, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer’s and Related Dementias Disease Risk
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer's and Related Dementias Disease Risk." This initiative aims to foster research that integrates epidemiologic, genomic, and mechanistic studies to uncover the molecular and cellular determinants of resilience against Alzheimer's disease (AD) and related dementias (ADRD) through data-driven, systems-based approaches, including artificial intelligence and machine learning. The program is particularly significant as it seeks to generate high-dimensional molecular data from brain and peripheral tissues, facilitating the discovery of molecular predictors of resilience across diverse populations. While applications are not currently being solicited, interested researchers are encouraged to prepare collaborative projects in anticipation of the opportunity, which is expected to utilize the U01 activity code. For further inquiries, potential applicants can contact Dr. Suzana Petanceska at petanceskas@nia.nih.gov or by phone at 301-496-9350. The estimated synopsis post date is February 26, 2026, with a projected award date of April 5, 2027.
    Notice of Intent to Publish a Notice of Funding Opportunity for Centers on the Demography and Economics of Aging and Alzheimer�s Disease and Alzheimer�s Disease Related Dementias Coordinating Center (U24 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for the establishment of a Coordinating Center focused on the Demography and Economics of Aging, including Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD). The objective of this cooperative agreement is to create a hub that facilitates collaboration among various D&E Centers, scholars, and the research community, enhancing the scientific impact and fostering synergies across related programs and infrastructures. This initiative is crucial for promoting an inclusive research environment and raising awareness about the demography and economics of aging. The estimated total program funding is $1,320,000, with an award ceiling of $800,000, and the application process is expected to open in July 2024, with submissions due by October 2024. Interested applicants should prepare to develop meaningful collaborations in advance of the application deadline.